Self-Immolative Phosphoramidates to Expand The Payload Scope in Antibody-Drug Conjugates by Delivery of Hydroxy-Containing Drugs
- Explore how payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors
- Present novel linker technologies for stable conjugation and traceless release of hydroxy-containing drugs to expand the payload space in ADCs
- Discuss how resulting ADCs are homogenous at high DAR, have excellent linker stability, and exhibit unprecedented in vivo PK and efficacy